rare diseases, autoimmune conditions, and other therapeutic areas. Moderna maintains a pipeline of vaccine and therapeutic candidates and utilizes a platform approach that combines mRNA design, delivery technologies, and manufacturing processes across multiple programs. The company also collaborates with research institutions, healthcare organizations, and industry partners to advance the development and evaluation of its mRNA-based medicines. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology.

Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.